[4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[(2E)-3-p-tolyl-acryloyl]-piperidin-4-yl}-acetic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[(2E)-3-p-tolyl-acryloyl]-piperidin-4-yl}-acetic acid
• 英文别名: (E)-2-(4-(1H-indol-3-yl)piperidin-1-yl)-2-(1-(3-p-tolylacryloyl)piperidin-4-yl)acetic acid；2-[4-(1H-indol-3-yl)piperidin-1-yl]-2-[1-[(E)-3-(4-methylphenyl)prop-2-enoyl]piperidin-4-yl]acetic acid
• 化学式: C₃₀H₃₅N₃O₃
• 分子量: 485.626
• InChiKey: AQZBOLMPADGBBR-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  76.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [4-(1H-indol-3-yl)-piperidin-1-yl]-piperidin-4-yl-acetic acid 、 (2E)-3-(4-甲基苯基)丙烯酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 [4-(1H-indol-3-yl)-piperidin-1-yl]-{1-[(2E)-3-p-tolyl-acryloyl]-piperidin-4-yl}-acetic acid
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationship and in Vivo Antiinflammatory Efficacy of Substituted Dipiperidines as CCR2 Antagonists

  摘要：

  A series of substituted dipiperidine compounds have been synthesized and identified as selective CCR2 antagonists. Combining the most favorable substituents led to the discovery of remarkably potent CCR2 antagonists displaying IC50 values in the nanomolar range. Compound 7a had outstanding selectivity over CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, and CCR8 and showed excellent efficacy in adjuvant-induced arthritis model, collagen-induced arthritis model, and allergic asthma model.

  DOI：

  10.1021/jm070902b

文献信息

• Synthesis, Structure−Activity Relationship and in Vivo Antiinflammatory Efficacy of Substituted Dipiperidines as CCR2 Antagonists
  作者：Mingde Xia、Cuifen Hou、Duane E. DeMong、Scott R. Pollack、Meng Pan、James A. Brackley、Nareshkumar Jain、Chrissy Gerchak、Monica Singer、Ravi Malaviya、Michele Matheis、Gil Olini、Druie Cavender、Michael Wachter

  DOI：10.1021/jm070902b

  日期：2007.11.1

  A series of substituted dipiperidine compounds have been synthesized and identified as selective CCR2 antagonists. Combining the most favorable substituents led to the discovery of remarkably potent CCR2 antagonists displaying IC50 values in the nanomolar range. Compound 7a had outstanding selectivity over CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, and CCR8 and showed excellent efficacy in adjuvant-induced arthritis model, collagen-induced arthritis model, and allergic asthma model.